ProCE Banner Activity

Therapeutic Relevance of HER3 in EGFR TKI-Resistant NSCLC

Slideset

Download these slides from an expert-led webinar on the scientific rationale for targeting HER3 in NSCLC

Released: April 03, 2023

Share

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Yasushi Goto, MD, PhD: consultant/advisor/speaker: Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Lilly, Merck, MSD, Novartis, Ono, Pfizer, Thermo Fisher; research grants (paid to institution): AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Kyorin, Novartis, Ono, Pfizer, Preferred Network; research grants (paid to clinical trial group): AZK, Pfizer; advisory board: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Guardant Health, Illumina, Lilly, MSD, Novartis, Ono, Pfizer, Taiho.